Recursion Pharmaceuticals Announces Acquisition of Full Rights to REV102, Aiming to Launch First Oral Therapy for Hypophosphatasia by 2026

Recursion Pharmaceuticals Inc. $(RXRX)$ has announced the acquisition of Rallybio's full interest in their joint ENPP1 inhibitor program, REV102, designed for the treatment of hypophosphatasia $(HPP)$, a rare genetic disorder. The acquisition includes an associated backup molecule. This move grants Recursion full ownership of the program, allowing the company to expedite the development of what could become the first oral disease-modifying therapy for HPP. Currently in IND-enabling studies, REV102 is expected to enter Phase 1 clinical trials in the second half of 2026. The program aims to address the underlying cause of HPP by inhibiting the enzyme ENPP1, potentially improving bone mineralization. Results of these studies have yet to be presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9490508-en) on July 08, 2025, and is solely responsible for the information contained therein.